SAVE THE DATE

Starlight Capital and APVA* Enterprise Pitch and Investor Networking Event Wednesday,  September 18, 2019

 

HESS Event Building

5430 Westheimer Rd.

Houston, TX  77056

Starlight Capital and APVA are pleased to invite you to our upcoming corporate presentation and investor networking forum will be held at The HESS Event Center, Houston, Texas, on Wednesday, September 18, 2019.  Up to 15 carefully selected technology companies will present their investment opportunity and answer questions. At past meetings technologies licensed from Texas A&M, Houston Methodist Research and MD Anderson have presented.  Sign-in will start at 11:00 am. The Banquet Luncheon will be served at noon and the meeting goes until 5:00 pm followed by cocktails, hors d’oeuvres and a jazz ensemble for attendees networking enjoyment will be served.

The “early-bird” investor registration fee is only $175. Registrants are allowed to bring up to two members of your firm or other “investor” guests at no charge. Please keep in mind that your guests must be bona fide active direct and accredited investors for their own personal account or that of the firm they represent, and may not include entrepreneurs seeking capital, vendors or service providers.

In order to make arrangements for your investor guests to attend, just send their names and business affiliation, if any, to me together with their e-mail addresses and phone numbers, and we will confirm their complimentary registrations on your behalf. As you may be aware, we provide a financial guarantee to the club with respect to each confirmed guest for the banquet luncheon. In addition, we certify the roster of investor participants to the presenting companies. Accordingly, when inviting your guests, thank you so much for letting them know that this is not an “I’ll drop in if I can make it event” and they should not RSVP unless that are quite sure that they can attend and stay for most of the entire function.

We are expecting 50+ guests, which will include many prominent people from the investment community. As we only have a few VIP guest tickets still available, thank you in advance for finalizing your arrangements to attend upon receipt of this confirmation in order to hold your reservation. Kindly note that admission to the forum as a VIP Guest requires this advance registration.  Alternatively, our standard Registration Fee of $275 would be applicable if seats are still available on the event date.

Click here to register.

I hope that you decide to join us there.

Steve Brewer, Founder and Executive Director

American Philanthropic Ventures Association, Inc.

(713) 443-3662, steve@asgib.com

Previous Events

  • March 9th, 2017 – APVA Medical Technology Luncheon [READ MORE]
  • February 16th, 2017 – APVA Medical Technology Conference [READ MORE]

APVA Medical Technology Conference
February 16th, 2017

APVA Med-Tech Conference at the Westin Galleria was a Great Success!

If you missed it, you still have the opportunity to learn, share and invest in the cutting edge technology that will help alleviate human suffering by becoming a member.

We met the most amazing people with a hearts of gold. From a technology that can diagnose various infectious diseases within minutes, such as Zika Virus infection, to a plant called, Hamelia Patens, that has active ingredients from various botanical extracts to target epidermal repair for UV-radiation, radiotherapy and major thermal burns.

Partner up with us to get the message out to the world, we exist to help these amazing inventors and developers and their technology reach the right investor(s) that will help take these companies to the people that need them the most “the patient”.

Life Sciences Presenters:

Dr. Don Berry, MD, Gary Gage, Stephen Brewer, APVA, Dr. Barry Griffin, DVM, Dr. Jay Coonan, MD

Company Bio’s

Dr. Jay Coonan, MD, Founder, Director, Strategy & Business Development, OvaGene Diagnostics

OvaGene Diagnostics Inc. develops Point of Care (POC) technologies licensed from Houston Methodist Research Institute and Texas A&M University to diagnose infectious diseases such as Zika virus infection and infections from antimicrobial resistant bacteria with a handheld device using bodily fluids such as a drop of blood. These molecular tests will improve the diagnosis and therapy selection of infectious diseases, utilizing a miniaturized, easily performed, rapid, self-contained, proprietary POC testing platform. The OvaGene Zika test is in the FDA regulatory Emergency Use Authorization program for rapid approval to address the urgent need for Zika virus infection diagnosis.

Dr. Barry Griffin, DVM, Founder & CEO, Clean Water Tech, LLC

Clean Water Tech, LLC was developed and is currently successfully used to treat oilfield fluids so that they can be recycled in the oil patch.  With APVA the technology will be designed to accomplish with you a mission of using this robust technology for treating contaminated drinking water sources to improve the health of under developed areas of the world.

Don Wayne Berry, MD, Founder & CEO, Berry Pharmaceuticals, LLC

Dr. Don Berry, a retired Texas heart  surgeon, was serendipitously introduced to a rainforest plant in 2004.  Dr. Berry  dedicated the last 12 years developing amazing new drugs now USPTO patented  from the botanical extracts of the rain forest plant, Hamelia patens. Active ingredients from various botanical extracts have been shown to target epidermal repair for UV-radiation, radiotherapy and major thermal burns. BP is preparing for clinical trials and is interested in meeting interested participants.”

Gary Gage, President & CEO, Stream Biomedical, Inc.

Stream Biomedical was founded to address unmet therapeutic needs for individuals suffering as a result of neurologic trauma or degeneration. Stream is commercializing a therapeutic protein which may be key to saving brain capacity and associated functions from debilitating neurologic experiences such as stroke, Alzheimer’s Disease and vascular dementia.

Have a sneak peek on the inside of our event at the Westin Galleria !

APVA Medical Technology Luncheon
March 9th, 2017

APVA Med -Tech Luncheon at the Post Oak Grill was Amazing!

If you missed it, you still have the opportunity to learn, share and invest in the cutting edge technology that will help alleviate human suffering by becoming a member. We met the most amazing people with a hearts of gold. From helping cancer survivors with fertility issues to a technology that can detect brain hypoxia in premature babies.

Partner up with us to get the message out to the world, we exist to help these amazing inventors and developers and their  technology reach the right investor(s) that will help take these companies to the people that need them the most “the patient”.

Life Sciences Presenters:

Leslie R. Schover, PhD, Graham L. Randall, PhD, MBA, Stephen Brewer, APVA President, Miguel Suderman, MSc

Company Bio’s

Miguel Suderman, MSc, President & CSO, Cell Systems 3-D, LLC

The Technology: First in kind human, veterinary and inset 3-D multi-tissue organoid models within controlled laboratory environment.

The Benefit: As a efficacy-toxicity indicator tool, three dimensional (3-D) laboratory-derived multi-tissue models could result in substantial experimental testing costs. These data confirmed specially bioengineered 3-D multi-tissue models can serve as predictive tools of the efficacy and toxicity of lead drug compounds while in the discovery-preclinical phase. Utilization of this 3-D cell culture technology will effectively streamline the drug development process

Leslie R. Schover, PhD, Founder, Will2Love, LLC

The Issue: Sexual and fertility side effects of cancer treatment

The Solution: Simple medical prescriptions rarely resolve the problems because a person or couple need to make changes in the sexual relationship. Will2Love provides self-help programs supplemented by telehealth counseling from trained professionals, providing easily accessible resources for patients and survivors. Professional portal offers training and guidance for oncology health care providers.

Graham Randall, Ph.D., MBA, President & CEO, Noninvasix, Inc.

The Technology: Noninvasix’s novel solution utilizes optoacoustic monitoring of cerebral venous oxygenation to accurately measure the amount of oxygen a baby is receiving in real time.

The Problem: Brain hypoxia is a major cause of death and permanent disability in newborns

The Solution: NeoVOX Brain Oxygenation Monitoring, it is noninvasive, suitable for neonates, easy to use, absolute values, venous oxygenation and sensitive to cerebral desaturations.

Have a sneak peek on the inside of our event at the Post Oak Grill!